Priorities for an optimal response to Pediatric Growth Hormone (hGH)

LIVE WEBINAR
5 May 2023
from 14.00 to 15.30 CEST
REGISTER
scroll-down-icon

Overview

Successful hGH administration can transform the life of a child who was destined to live with significant short stature into an adolescent facing adulthood confidently with height within the normal range. The aims of this webinar are to discuss how to optimize benefit from rhGH, which is dependent on three key factors.

Firstly, investigation must identify the children with GH deficiency who are likely to respond best to rhGH treatment. Secondly, it is now clear that adherence to the standard hGH injection regimen is subnormal in a large number of patients, impacting their clinical growth response. Understanding the causes and psychopathology of poor adherence is a major component of hGH management, and clinician and care team input and support to address this issue is crucial to treatment success. Finally, a major advance has recently occurred with the development and marketing of LAGH leading to weekly, rather than daily administration. As clinical experience with this new therapy remains limited, this webinar will provide information on the new therapies, and an opportunity for discussion with clinicians who have experience of the new treatments.

Learning Objectives

After attending the live webinar participants will be able to:

  • • Explain the benefits of a skilled clinical assessment, and the role of biochemical screening, endocrine evaluation and genetic studies in the assessment of a child with short stature
  • • Improve the understanding of the safety and efficacy of GH administered once daily in managing patients with short stature
  • • Increase the understanding of the relationship between adherence to daily GH and treatment outcomes
  • • Expand clinical and psychological management techniques to improve poor medication adherence with hGH
  • • Increase awareness of the emerging science of LAGHs to improve the understanding of their efficacy, safety and potential clinical applicability.

Target Audience

Pediatricians, endocrinologists and clinicians involved in growth management.

Accreditation

The Priorities for an optimal response to Pediatric Growth Hormone (hGH), Rome, Italy, 05/05/2023-05/05/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

The content of the “Priorities for an optimal response to Pediatric Growth Hormone (hGH), Online 5th May 2023” has been certified by the CPD Certification Service as conforming to continuing professional development principles.

 

Priorities for an optimal response to Pediatric Growth Hormone (hGH)

LIVE WEBINAR

Friday, 5 May 2023

from 14.00 to 15.30 CEST

Language

The official language of this live educational activity is English.
eng

Faculty

Martin Savage

Emeritus Professor of Paediatric Endocrinology
William Harvey Research Institute
Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, UK

Marco Cappa

Professor of Pediatrics at “Tor Vergata” University of Rome, Italy
and Professor of Endocrinology at “La Sapienza” University of Rome, Italy

Justin Davies

Honorary Professor of Paediatric Endocrinology at the University of Southampton, UK
Head of Department at the Regional Centre for Paediatric Endocrinology at Southampton Children’s Hospital, UK

Cheri Deal

Emeritus Professor, University of Montreal
Pediatric Endocrinologist and Associate Member
Research Center, CHU Ste-Justine
Montreal, Canada

Richard Ross

Professor of Endocrinology University of Sheffield
Sheffield, UK

John Weinman

Professor of Psychology applied to Medicines, and Director of the Centre for Adherence Research & Education at King’s College London
London, UK

Agenda

Registration

For registration CLICK HERE

REGISTRATION IS FREE OF CHARGE

Save the date

Download PDF
FUNDING

· Carlo Alviggi ·

Carlo Alviggi earned his MD degree in 1994, from the Faculty of Medicine of the University of Naples “Federico II” in Naples, Italy; he specialized in obstetrics and gynaecology in 1998, and gained a PhD in 2001, from the same university. During his career, he collaborated with: The Imperial College of London, in London, UK; the Laboratory of Immunology of the Italian National Research Council in Naples; and the Autoimmunity and Tolerance Laboratory of the University of California in Los Angeles, CA, USA. This network resulted in various publications, some of which concern new hypotheses on the pathogenesis of pelvic endometriosis. He is now an associate professor in reproductive medicine at the Fertility Unit of the University of Naples “Federico II”. Professor Alviggi’s current research interests are the role of luteinizing hormone (LH) in folliculogenesis; the use of LH-containing drugs in patients undergoing ovarian controlled stimulation for IVF; the pathogenesis of pelvic endometriosis; oncofertility; reproductive endicrinology and the genetics of human reproduction. He has participated in several national and international (phase 2 and 3) multicentric, prospective randomized trials. Professor Alviggi has published extensively and has been invited to lecture at over 200 international meetings dealing with reproductive medicine and gynaecological endocrinology; he is also starter and co-founder of the Poseidon group, an international collaborative network dedicated to low prognosis patients in Assisted Reproductive Technology and vice-President of the “Società Italiana di Fertilità e Sterilità – Medicina della Riproduzione”.

· Robert Fischer ·

Robert Fischer is the founder and Medical Director of the Fertility Center Hamburg (FCH) in Hamburg, Germany. Dr Fischer trained in obstetrics and gynaecology at the University Hospital of Münster, Germany, from 1979 to 1982 and at the Queen’s Medical Centre, University of Nottingham, UK. In 1983, Dr Fischer pioneered the first German outpatient IVF unit in Hamburg and became its Medical Director. The unit moved to a new location in 1998, and its name was changed to the “Fertility Center Hamburg”.

In July 1998, the Fertility Center Hamburg was one of the first centres, both in Germany and worldwide, to introduce quality management, and it was certified according to the ISO 9001 and accredited for IVF laboratories (ISO 17025). Dr Fischer’s main research interests are in the development of stimulation protocols, luteinizing hormone supplementation, and gonadotropin-releasing hormone agonist triggering, as well as further development of quality management systems in IVF centres. He is a founding member of the European Society of Human Reproduction and Embryology (ESHRE); a founding member of the POSEIDON (Patient Oriented Strategies Encompassing IndividualizeD Oocyte Number) group);  Member of the  Scientific Committee of Excellence in Medical Education (EXCEMED- formerly the Serono Symposia International Foundation) and Scientific director of  Med.E.A.( Medical Education Academy)

· Peng Cheang Wong ·

Peng Cheang Wong is the Professor of Obstetrics & Gynaecology in the Yong Loo Lin School of Medicine and a Senior Consultant in the National University Hospital. He was the Head of the Division of Reproductive

Endocrinology & Infertility in the National University Hospital from 2001 to 2017 and the Director of the Assisted Reproductive Technologies (ART) Programme in the National University Hospital, Singapore. He was also the founding Director of the Centre for Reproductive Education & Specialist Training (CREST) until 2017 and the first President of the Asia-Pacific Initiative on Reproduction (ASPIRE) from 2006 – 2008. He is active in postgraduate education in the field of ART and has conducted and participated in numerous courses in the region.

· Sandro C. Esteves ·

Sandro Esteves, MD., Ph.D. is a board-certified urologist and consultant in assisted reproduction with over 25 years of clinical experience in all areas of reproductive medicine, with specialization in male reproduction.

He is listed by Expertscape among the top three world experts in the areas of male infertility, azoospermia, varicocele, and sperm retrieval techniques. Sandro has been also included in the list of the world’s most influential scientists.

He is the Founder and Medical Director of the ANDROFERT Andrology & Human Reproduction Clinic, in Campinas, Brazil. Dr. Esteves established the first Brazilian Fertility Clinic with a primary focus on male infertility, as well as the very first to introduce quality management as per the ISO 9001 standards and IVF cleanroom technology (ISO 14644-1).

Sandro is also a Collaborating Professor of Urology at the University of Campinas (UNICAMP, Brazil) and Honorary Professor of Reproductive Medicine at Aarhus University (Denmark). Dr. Esteves received his Master’s in Surgery from the University of Campinas Medical School and his Ph.D. in Urology from the Federal University of São Paulo Medical School. His post-doctoral training was at the American Center for Reproductive Medicine at the Cleveland Clinic in the United States. He has received many research grants and awards from national and international societies.

Prof. Esteves is the author of 10 textbooks in the fields of infertility and reproductive medicine. He was also the co-editor of several Journal Supplements and has published over 400 hundred scientific papers in journals like Lancet, Nature, Human Reproduction Update, Human Reproduction, Fertility and Sterility, etc. His current Hirsch index (h-index) is 63 while his citation count is over 12K. He is a member of ‘Faculty Opinions’ in the area of reproductive endocrinology & infertility. Dr. Esteves is Associate Editor of Frontiers in Endocrinology (Reproduction), Andrology, International Brazilian Journal of Urology, Regional Editor of the Société Internationale d’Urologie Journal, an editorial board member of Nature Reviews Urology, and a dozen of other peer-reviewed scientific journals. He is also a co-founder of the POSEIDON group and currently serves as a Chair of the Male Infertility Section of the WHO Infertility Guidelines Development Group.

Dr. Esteves is a very much requested speaker and presents over 50 lectures annually. He also regularly conducts infertility workshops, provides consulting services in the area of quality management for ART Clinics,

· Peter Humaidan ·

Professor Peter Humaidan is a specialist in reproductive endocrinology, professor at The Fertility Clinic Skive Regional Hospital, Aarhus University, Denmark and Honorary professor at Odense University, Denmark. During his scientific work he has primarily focused on developing individualized treatment protocols for the infertile patient. His doctoral thesis (DMSc) explored the role of LH during the follicular and luteal phases in controlled ovarian stimulation. His main fields of interest are triggering of ovulation with GnRH agonist, role of LH during the follicular and luteal phases, role of the female genital tract microbiota for reproductive outcomes, OHSS prevention, and role of sperm DNA fragmentation for spontaneous and assisted reproduction. He is the founder of the international society “The Copenhagen GnRHa Triggering Workshop Group” who introduced the GnRHa trigger in modern IVF, changing trigger policies worldwide. Moreover, he is co-founder of the POSEIDON group which suggested a new stratification of the poor responder patient, and a past board member of the ESHRE SIG Endocrinology Group. He is in the Elsevier, Stanford global list of 2% top scientists, and he authored and co-authored 250 + articles (H-index 67, Google Scholar) in international peer reviewed journals as well as chapters in textbooks and the Danish guidelines for OHSS prevention. Peter Humaidan has a wide international scientific network and is frequently invited as a speaker at international conferences.